"There were no statistically significant differences between the 
groups of patients initially assigned to any of the five (first and 
second generation) antipsychotics in the proportion of patients who 
received inpatient care each month or in costs per month for 
inpatient, residential, or outpatient health services."

http://pn.psychiatryonline.org/cgi/content/short/41/23/1-a

"Most important of "the lessons learned" is the calculation of lower 
costs for perphenazine and the ability to see "how much the costs of 
treatment for chronic schizophrenia are driven by the costs of the drugs."

"Most disappointing, the editorialists said, is the notion that 
hundreds of millions of dollars and many years were spent to give 
clinicians and  patients a new generation of "better" medications. 
Yet the new drugs appear to be no more effective than some earlier 
ones, and CATIE clearly showed that "the side effect burden has 
shifted, not disappeared.""

http://pn.psychiatryonline.org/cgi/content/full/psychnews;41/23/59


"People Who experience mood swings, fear, voices and visions"